Sign up to save your podcasts
Or
Share #37 How many lives would be changed with effective prevention of thromboembolic events? John Glasspool, CEO of Anthos Therapeutics
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
#37 How many lives would be changed with effective prevention of thromboembolic events? John Glasspool, CEO of Anthos Therapeutics
An interview with John Glasspool, CEO of Anthos Therapeutics. Did you know that VTE is the 2nd leading cause of death in cancer patients after the cancer itself? Did you know that many patients choose not to us the current standard of care to blood clotting due to excessive bleeding? Anthos Therapeutics is addressing this major unmet medical need in thromboembolic events with their lead candidate abelacimab. Abelacimab is an investigational monoclonal antibody that achieves profound suppression of the novel antithrombotic target Factor XI.
https://anthostherapeutics.com/
https://thebiotechiqpodcast.com/
Check me out on LinkedIn https://www.linkedin.com/in/ammonr/
View all episodes
By Ammon RiveraAn interview with John Glasspool, CEO of Anthos Therapeutics. Did you know that VTE is the 2nd leading cause of death in cancer patients after the cancer itself? Did you know that many patients choose not to us the current standard of care to blood clotting due to excessive bleeding? Anthos Therapeutics is addressing this major unmet medical need in thromboembolic events with their lead candidate abelacimab. Abelacimab is an investigational monoclonal antibody that achieves profound suppression of the novel antithrombotic target Factor XI.
https://anthostherapeutics.com/
https://thebiotechiqpodcast.com/
Check me out on LinkedIn https://www.linkedin.com/in/ammonr/